Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.
Modernism played an undeniable role in the renewal of architectural ideals, contributing a new attitude toward understanding ...
Promovida pela MRV, a campanha busca incentivar os clientes a realizarem o sonho da casa própria antes do reajuste de preços do início de 2025 A MRV, empresa do grupo MRV&CO e maior construtora ...
Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...
MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results